US1140822099

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

July 14, 2026 09:01 ET  | Source: Ernexa Therapeutics Inc. CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into…

7 days ago

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

February 20, 2026 09:05 ET  | Source: Ernexa Therapeutics Inc. Live video webcast with Sanjeev Luther, President and Chief Executive…

5 months ago

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

February 06, 2026 09:25 ET  | Source: Ernexa Therapeutics Inc. CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics…

5 months ago

Ernexa Therapeutics to Present at Oxford Globals Cell 2025

Sanjeev Luther, President and CEO to give an oral presentation and participate in a moderated panel discussion November 11, 2025…

8 months ago